Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33795870.
- Also identified by DOI 10.1038/s41591-021-01325-6 and PMC identifier 8205849.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Medical subject headings
- Antibodies, Viral
- Antigens, Viral
- COVID-19
- COVID-19 Vaccines
- Coronavirus Nucleocapsid Proteins
- Immunoglobulin G
- Immunoglobulin M
- SARS-CoV-2
- Spike Glycoprotein, Coronavirus